<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2186">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656733</url>
  </required_header>
  <id_info>
    <org_study_id>11-057-6</org_study_id>
    <secondary_id>1R01HD069314-01A1</secondary_id>
    <nct_id>NCT01656733</nct_id>
  </id_info>
  <brief_title>Nicotine Replacement for Smoking Cessation During Pregnancy</brief_title>
  <official_title>Nicotine Replacement for Smoking Cessation During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial to determine if the nicotine inhaler in combination with counseling&#xD;
      will help pregnant women quit smoking, and whether it is safe when compared to placebo (an&#xD;
      inactive inhaler).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project will examine the safety and efficacy of the nicotine inhaler as an aid to&#xD;
      smoking cessation during pregnancy. The specific aims are: (1) To examine the efficacy of the&#xD;
      nicotine inhaler compared to a matching placebo for smoking cessation during pregnancy; (2)&#xD;
      To compare the nicotine inhaler with placebo on overall nicotine exposure (i.e., serum&#xD;
      cotinine concentrations), and on birth outcomes (i.e., birth weight and gestational age); (3)&#xD;
      To identify factors that determine which women benefit most from the use of the nicotine&#xD;
      inhaler for smoking cessation during pregnancy; (4) To explore mechanisms by which the&#xD;
      nicotine inhaler increases birth weight and gestational age.&#xD;
&#xD;
      Subjects will be recruited from two prenatal clinics that serve primarily a low-income,&#xD;
      minority population.&#xD;
&#xD;
      Pregnant smokers (n=270) who smoke at least 5 cigarettes/ day will receive nurse-delivered&#xD;
      behavioral counseling and be randomized to receive a 6-week course of treatment with either a&#xD;
      nicotine inhaler or placebo, followed by a 6-week taper. Birth outcomes will be obtained on&#xD;
      all participants&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 25, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Self Report an Average of Zero Cigarettes Smoked Per Day in Preceding 7 Days</measure>
    <time_frame>32-34 weeks gestation (Visit 6)</time_frame>
    <description>Number of participants who self report an average of zero cigarettes smoked per day in preceding 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled Carbon Monoxide</measure>
    <time_frame>32-34 weeks gestation</time_frame>
    <description>As measured by parts per million (ppm) on CO breathalyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth Weight</measure>
    <time_frame>At delivery</time_frame>
    <description>Birth weight in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age</measure>
    <time_frame>At delivery</time_frame>
    <description>Measure of age of pregnancy at delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Nicotrol Inhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Inhaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotrol Inhaler</intervention_name>
    <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper</description>
    <arm_group_label>Nicotrol Inhaler</arm_group_label>
    <other_name>Nicotine Inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Inhaler</intervention_name>
    <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper</description>
    <arm_group_label>Placebo Inhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  smoking at least 5 cigarettes per day for the preceding 7 days&#xD;
&#xD;
          -  previous attempt to quit smoking during pregnancy by self report&#xD;
&#xD;
          -  13-26 weeks gestation&#xD;
&#xD;
          -  at least 16 years of age&#xD;
&#xD;
          -  able to speak English or Spanish&#xD;
&#xD;
          -  intent to carry pregnancy to term&#xD;
&#xD;
          -  stable residence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current drug or alcohol abuse or dependence (other than methadone maintenance)&#xD;
&#xD;
          -  twins or other multiple gestation&#xD;
&#xD;
          -  unstable psychiatric disorder&#xD;
&#xD;
          -  unstable medical problems (e.g., pre-eclampsia, threatened abortion, hyperemesis&#xD;
             gravidarum)&#xD;
&#xD;
          -  known congenital abnormality&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheryl Oncken, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Ambulatory Health Services at Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesson Women's Clinic at Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <results_first_submitted>January 31, 2019</results_first_submitted>
  <results_first_submitted_qc>September 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2019</results_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Cheryl Oncken</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Nicotrol Inhaler</keyword>
  <keyword>Placebo Inhaler</keyword>
  <keyword>Nicotine Inhaler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT01656733/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited beginning August 20, 2012. Enrollment sites included Hartford Hospital (Hartford, CT) and Baystate Medical Center (Springfield, MA).</recruitment_details>
      <pre_assignment_details>154 participants gave written consent for study participation and 137 were randomized. Therefore, 17 participants were excluded for the following reasons: no show after screen (10), high PHQ9 (2), moved out of area (2), current drug use (1), advanced gestational age (1), and stress too high to continue (1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Inhaler</title>
          <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper&#xD;
Nicotrol Inhaler: Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper Placebo Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
        </group>
        <group group_id="P2">
          <title>Nicotrol Inhaler</title>
          <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.&#xD;
Nicotrol Inhaler: Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper Placebo Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67">4 discontinued after BL visit (lost to follow up)</participants>
                <participants group_id="P2" count="70">5 discontinued after BL visit ( lost to follow up)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 1 (1 Week After Quit Date)</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 2 (2 Weeks After Quit Date)</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 3 (3 Weeks After Quit Date)</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 4 (4 Weeks After Quit Date)</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 5 (6 Weeks After Quit Date)</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 6 ( 32-36 Weeks Gestation)</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants With Perinatal Outcomes</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 7 (1 Month Postpartum) Phone Call</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 8 (6 Months Postpartum)</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No permission to collect birth outcomes</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Delivery at another hospital</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Spontaneous abortion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Inhaler</title>
          <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper</description>
        </group>
        <group group_id="B2">
          <title>Nicotrol Inhaler</title>
          <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.24" spread="6.30"/>
                    <measurement group_id="B2" value="26.97" spread="5.45"/>
                    <measurement group_id="B3" value="27.59" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic, White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic, Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highest level of education completed</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade School Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High School Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College or post college completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Cigs/day</title>
          <description>number of cigarettes per day reported at baseline</description>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.04" spread="4.59"/>
                    <measurement group_id="B2" value="8.66" spread="4.71"/>
                    <measurement group_id="B3" value="8.36" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of cigarettes per day last two weeks</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.03" spread="4.69"/>
                    <measurement group_id="B2" value="3.48" spread="3.29"/>
                    <measurement group_id="B3" value="4.14" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Self Report an Average of Zero Cigarettes Smoked Per Day in Preceding 7 Days</title>
        <description>Number of participants who self report an average of zero cigarettes smoked per day in preceding 7 days</description>
        <time_frame>32-34 weeks gestation (Visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Inhaler</title>
            <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper</description>
          </group>
          <group group_id="O2">
            <title>Nicotrol Inhaler</title>
            <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Self Report an Average of Zero Cigarettes Smoked Per Day in Preceding 7 Days</title>
          <description>Number of participants who self report an average of zero cigarettes smoked per day in preceding 7 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Carbon Monoxide</title>
        <description>As measured by parts per million (ppm) on CO breathalyzer</description>
        <time_frame>32-34 weeks gestation</time_frame>
        <population>Overall number of participants includes only those that attended the 32-34 gestation week visit</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Inhaler</title>
            <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper</description>
          </group>
          <group group_id="O2">
            <title>Nicotrol Inhaler</title>
            <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Carbon Monoxide</title>
          <description>As measured by parts per million (ppm) on CO breathalyzer</description>
          <population>Overall number of participants includes only those that attended the 32-34 gestation week visit</population>
          <units>parts per million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="5.42"/>
                    <measurement group_id="O2" value="6.7" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birth Weight</title>
        <description>Birth weight in grams</description>
        <time_frame>At delivery</time_frame>
        <population>Could not obtain birth outcomes on 4 individuals in nicotine group for various reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Inhaler</title>
            <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper</description>
          </group>
          <group group_id="O2">
            <title>Nicotrol Inhaler</title>
            <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight</title>
          <description>Birth weight in grams</description>
          <population>Could not obtain birth outcomes on 4 individuals in nicotine group for various reasons.</population>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3036.78" spread="583.8"/>
                    <measurement group_id="O2" value="3141.12" spread="561.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age</title>
        <description>Measure of age of pregnancy at delivery</description>
        <time_frame>At delivery</time_frame>
        <population>Could not obtain birth outcomes on 4 individuals in nicotine group for various reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Inhaler</title>
            <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper</description>
          </group>
          <group group_id="O2">
            <title>Nicotrol Inhaler</title>
            <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age</title>
          <description>Measure of age of pregnancy at delivery</description>
          <population>Could not obtain birth outcomes on 4 individuals in nicotine group for various reasons.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.61" spread="2.53"/>
                    <measurement group_id="O2" value="39.11" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from baseline visit up to delivery of infant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Inhaler</title>
          <description>Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper&#xD;
Nicotrol Inhaler: Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper Placebo Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
        </group>
        <group group_id="E2">
          <title>Nicotrol Inhaler</title>
          <description>Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.&#xD;
Nicotrol Inhaler: Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper Placebo Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Fetal Cardiac Anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Infant Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Right Club Foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Infant Low Blood Sugar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Low Birth Weigh (&lt;2500 grams)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Preterm delivery</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Spontaneous Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Perinatal Mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neonatal Abstinence Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Maternal Hospitalizationfor Medical Condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infant Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bad taste</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Increased mucus in throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cheryl Oncken, MD, MPH</name_or_title>
      <organization>University of Connecticut School of Medicine</organization>
      <phone>860-679-3425</phone>
      <email>oncken@uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

